| Name | Title | Contact Details |
|---|
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world`s leading causes of blindness. Glaukos has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. The company launched the iStent Trabecular Micro-Bypass Stent, its first MIGS device, in the United States in 2012. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. Glaukos believes the iStent is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, the company completed an initial public offering and its shares are now traded on the New York Stock Exchange under the ticker symbol "GKOS". Founded in 1998, Glaukos is based in San Clemente, California.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
PRIO Corporation is a Beaverton, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom`Up designs hemostatic products based on patented biopolymers that aim to simplify surgical procedures in numerous specialties (spine, cardiothoracic, general, orthopedic, plastic) and give patients a better quality of life.
Vanguard Advanced Pharmacy Systems Inc is a Bradenton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.